Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 3.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 43,996 shares of the company’s stock after acquiring an additional 1,629 shares during the period. American Century Companies Inc. owned about 0.15% of Dianthus Therapeutics worth $959,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. R Squared Ltd purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $26,000. KBC Group NV purchased a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $35,000. AlphaQuest LLC raised its holdings in shares of Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after acquiring an additional 3,072 shares during the last quarter. Intech Investment Management LLC acquired a new position in Dianthus Therapeutics in the 4th quarter valued at $201,000. Finally, SG Americas Securities LLC lifted its stake in shares of Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after buying an additional 814 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 4.5 %

NASDAQ:DNTH opened at $15.60 on Friday. The stock has a fifty day moving average price of $20.76 and a 200 day moving average price of $23.45. Dianthus Therapeutics, Inc. has a 12-month low of $13.37 and a 12-month high of $32.27. The firm has a market cap of $501.15 million, a PE ratio of -6.24 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, Guggenheim restated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.